{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27"}]}],"title":"Acute GVHD: Grade 1-2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Acute GVHD: Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Chronic extensive GVHD"}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"groups":[{"description":"See Detailed Description\n\nrituximab: Given IV\n\ncyclosporine: Given orally\n\nfludarabine phosphate: Given IV\n\nmycophenolate mofetil: Given orally\n\nyttrium Y 90 ibritumomab tiuxetan: Given IV\n\nperipheral blood stem cell transplantation: Undergo transplantation\n\nallogeneic hematopoietic stem cell transplantation: Undergo transplantation\n\ntotal-body irradiation: Undergo TBI","id":"OG000","title":"Treatment (90Y Ibritumomab Tiuxetan, Hematopoietic Transplant)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"At day +84","title":"Incidence and Severity of Acute Graft-versus-host Disease (GVHD) and Chronic GVHD.","type":"SECONDARY","unitOfMeasure":"Participants"}